Renal Denervation Market Will Escalate to $677 M by 2022

Thursday 30 June 2016, Amsterdam

The global market for renal denervation, a procedure involving the ablation of renal artery nerves to reduce hypertension in drug-resistant cases, is set to grow from $64.9 million in 2015 to $677.4 million by 2022, representing a very rapid compound annual growth rate of 44.2%.

The company’s latest report* states that this significant expansion can be attributed to a reinvigoration of the treatment space following a damaging freeze in the market in January 2014. This occurred after Medtronic, the first company to enter the renal denervation market, suffered a serious setback as its Simplicity HTN-3 clinical trial failed to meet primary efficacy endpoints. Several companies stopped marketing their products and other clinical trials were stopped or terminated.

Brigitte Babin, MSc, says the industry has slowly started to recover, with multiple trials being launched worldwide, indicating that renal denervation is still believed to be a promising market.

Babin comments: “The procedure is important in treating the ever-growing global prevalence of hypertension, which puts considerable strain on healthcare systems due to its being a leading factor of cardiovascular disease including heart attack and stroke. In addition to treating hypertension, renal denervation is being investigated for the treatment of other indications related to a hyperactive sympathetic nervous system drive.

“Currently, it is only approved for patients with primary hypertension and excludes anyone with kidney disease, diabetes, or other conditions that may be causing the hypertension. The approval of these expanded indications would create a large growth opportunity within the treatment space.”

In terms of market share over the forecast period, Medtronic is expected to continue its domination of a significant portion of the market, having been the first major player to commercialize a renal denervation system.

Babin continues: “Despite Medtronic’s commanding position, there are a number of medical companies, both large and small, specifically focused on renal denervation. These companies are developing new systems and will compete with more established leaders of the field, aiding the upcoming revival of the renal denervation space.”

*MediPoint: Renal Denervation - Global Analysis and Market Forecasts

This report provides analysis of the renal denervation space across the 15 major markets of the US, France, Germany, Italy, Spain, UK, Japan, China, India, Brazil, Australia, Canada, Mexico, Russia, and South Korea, including annualized market data from 2015 and forecast until 2022.